Skip to content

Cagrilintide: Amylin Research, Monotherapy and CagriSema Evidence

Cagrilintide is a long-acting amylin analogue studied alone and with semaglutide. Human trial findings are substantial, but combination results cannot be assigned to cagrilintide alone or to an unverified blend.

By Peptide Mag Editorial. Updated . Source and review policy.

Identity
Long-acting amylin analogue
Monotherapy research
706-participant phase 2 trial
Combination research
REDEFINE 1: 3,417 randomized participants

The Simple Truth

Why this exists and what it’s supposed to do.

Cagrilintide exists because appetite has more than one off switch.

When you eat, your pancreas releases amylin alongside insulin, and amylin is part of how your brain registers fullness. Natural amylin is useless as a drug — it clumps in solution.

What it is supposed to do: reduce appetite through a pathway separate from GLP-1, so it can be used on its own or stacked with a GLP drug for more effect than either alone. The combination with semaglutide is the version in active trials.

This one has real human trial data behind it, which is unusual among the compounds on this site. It remains investigational.

Amylin analogue, not another name for semaglutide

Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone involved in satiety. It is not semaglutide and is not simply a different brand of a GLP-1 receptor agonist. Its different pharmacology explains the interest in studying it both alone and alongside semaglutide, but a plausible complementary mechanism does not establish the outcome of every combination.

The 2021 phase 2 paper and the REDEFINE 1 combination trial are distinct studies. Keeping their interventions separate prevents a common error: presenting a result achieved by a specified combination as if it were an established result of cagrilintide alone or of any seller's premixed product.

The phase 2 monotherapy signal

The multicenter phase 2 study randomized 706 adults without diabetes who had obesity, or overweight with hypertension or dyslipidemia. It assessed subcutaneous cagrilintide, placebo and an active liraglutide comparator over 26 weeks. Across cagrilintide groups, mean weight reduction ranged from 6.0% to 10.8%, compared with 3.0% for placebo under the trial-product estimand.

The highest studied group also had greater mean reduction than the active comparator in this experiment. That result does not establish superiority over every obesity medicine or predict an individual's response. Gastrointestinal events and administration-site reactions were important tolerability findings. The paper's masking details and its trial-product analysis should accompany interpretations rather than being lost behind one headline percentage.

REDEFINE 1 tested the combination directly

The 2025 REDEFINE 1 report randomized 3,417 adults with overweight or obesity without diabetes among cagrilintide-semaglutide, semaglutide alone, cagrilintide alone and placebo. All groups received lifestyle intervention. At 68 weeks, estimated mean body-weight change with the combination was −20.4%, versus −3.0% with placebo under the treatment-policy estimand.

This is a result for a specified coadministered intervention, not evidence that cagrilintide alone caused a 20.4% reduction. Gastrointestinal adverse events occurred in 79.6% of the combination group and 39.9% of the placebo group, mostly transient and mild to moderate. Efficacy and tolerability belong in the same summary; the latter should not disappear when the former becomes a headline.

Why analysis and formulation both matter

Treatment-policy and trial-product estimates answer different questions about events such as stopping treatment. A result calculated assuming adherence should not be silently compared with another result that includes outcomes after discontinuation. Likewise, percentages measured at 26 and 68 weeks do not represent a direct head-to-head ranking. Time, population, comparator and analysis need to travel with the number.

The combination's name also does not validate an independently manufactured blend. Coformulation raises questions about compatibility, concentration, stability, manufacturing and exposure that a familiar ingredient list cannot answer. A product needs its own relevant quality evidence. Recognizing both ingredient names is not equivalent to demonstrating that the material matches a clinical-trial intervention.

Why component arms are valuable

Including component arms is scientifically important because it lets a combination program investigate more than whether the combined intervention beats placebo. It creates a basis for separating contributions within the trial rather than relying solely on a mechanistic story. That design advantage should not be overextended: it still does not authenticate a supplier formulation or prove that independently changing component proportions preserves the observed effect. Product matching remains a separate question.

Current status and unanswered questions

The FDA's current notice states that cagrilintide is not a component of an FDA-approved drug and has not been found safe and effective for any condition; it also addresses compounding restrictions. Human research can be encouraging while a substance remains investigational. This profile does not provide a treatment or escalation schedule.

Is cagrilintide proven to work alone? The phase 2 study provides randomized human evidence of weight reduction under its conditions. Is that the same evidence as CagriSema? No: the combination is a different intervention. Are long-term outcomes settled? The studies summarized here do not establish every cardiovascular, maintenance or rare-safety outcome. The next useful question is which exact intervention and endpoint a claim is supported by—not whether a compound can be labeled simply good or bad.

Sources and further reading

  1. Cagrilintide phase 2 trial, 2021
  2. REDEFINE 1 original report, 2025
  3. FDA unapproved-drug notice

Continue reading